Literature DB >> 3381072

[Clinical course and risk factors in patients with generalized mycoses].

M von Eiff1, M Essink, W Fegeler, S Schellong, H Schmidt, W Hiddemann, T Büchner, J van de Loo.   

Abstract

A retrospective analysis of the clinical course of disseminated fungal infections in 32 patients revealed 25 cases of candidiasis, 5 patients with aspergillosis, and 2 with mixed fungal infections. All patients had undergone cytostatic therapy for malignant hematological diseases as the predisposing risk factor for fungal infection. 30 patients had severe granulocytopenia (less than 500/cmm). In addition, 30 patients had received broad spectrum antibiotics and 16 had been treated with corticosteroids. 17 of 32 patients were treated systemically with antimycotic drugs for proven fungal infection. No antimycotic agents were given to 15 patients because fungal infections were diagnosed only on post mortem examination. 19 patients succumbed to overwhelming disease, including 5 in spite of antimycotic therapy. Patients in whom systemic candidiasis was detected after recovery of granulocytopoeisis had a better prognosis than patients who developed systemic fungal infections during the period of ongoing severe granulocytopenia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3381072

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  4 in total

Review 1.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

Review 2.  Diagnosis of invasive mycoses in severely immunosuppressed patients.

Authors:  R Rüchel
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

3.  Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies.

Authors:  M von Eiff; M Essink; N Roos; W Hiddemann; T Büchner; J van de Loo
Journal:  Blut       Date:  1990-04

4.  Invasive aspergillosis complicating induction chemotherapy of childhood leukaemia.

Authors:  T Bömelburg; N Roos; H J von Lengerke; J Ritter
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.